Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...
Step inside the lounge at Evolved Science and you’ll find a cocktail menu unlike any you’ve ever seen. The ritzy Manhattan medical office — which says it serves high-powered clients and celebrities — ...
Discover how modern immunotherapy awakens T cells to shrink melanoma tumors, tracked by PET scans and used after surgery to prevent relapse. In this segment, Dr. Morrison provides clinical context ...
After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
While Eli Lilly’s investigational monoclonal antibody drug, bamlanivimab, just received FDA emergency approval to treat mild coronavirus patients, top officials voiced concerns over its challenging IV ...
Original Medicare provides coverage for IV infusion therapy when a doctor determines it to be medically necessary, both in a clinic setting and at home. Medicare Advantage (Part C) plans need to offer ...
OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results